Overview

• Over 1,000 South Australian volunteers have been genotyped and grouped into high- and low-risk cohorts for the study
• The recall by genotype approach selects participants based on MS-linked genetic variants to investigate preclinical biological differences
• Investigators are probing whether varied immune reactions to Epstein-Barr virus act as a trigger in genetically susceptible individuals
• Ethical guidelines are being drafted to govern disclosure of non-actionable genetic risk findings to study participants
• Funded by an MS Australia Incubator Grant, the pilot aims to identify early biomarkers to support future diagnostic tools and prevention strategies